Jefferies reiterates Buy on AbCellera stock, $21 target on VMS therapy
Jefferies maintained a Buy rating and $21 price target for AbCellera Biologics (NASDAQ:ABCL), citing potential in its VMS therapy. The stock is at $11.40, below analyst targets. Q3 revenue rose to $10.6M, beating estimates, with a narrower net loss. ABCL635 showed promising data, and late-stage development is planned for 2027. The company has over $890M in liquidity.
How this was made
The 30-second read
Why it matters
The earnings beat and analyst upgrade are likely to attract buying pressure, especially given the company's strong cash position and upcoming late‑stage trial data.
Market read
Earnings beat and higher target provide a fresh catalyst for ABCL, making it a short‑term buying opportunity.
What to watch
Potential execution risk in late‑stage trials and cash burn could limit upside.
Background
AbCellera Biologics (NASDAQ:ABCL) reported Q3 results with revenue of $10.6 M versus $6.21 M consensus and a narrower loss, while Jefferies raised its price target to $21.
Ticker impact
Jefferies reiterated a Buy rating and raised its price target to $21, citing Q3 earnings beat and encouraging late‑stage data for ABCL635.
upward pressure as the market prices in the earnings beat and higher target.
The stock beat revenue and loss expectations, and Jefferies lifted its target, which typically drives buying interest.
Market effects
Positive signal for biotech sector as a peer shows strong data and earnings beat.
North American biotech stocks may see modest gains.
Limited to investors focused on early‑stage biotech pipelines.
Counterpoint
The stock remains highly volatile and the earnings beat was modest; valuation may still be stretched.
Key entities
- companyAbCellera Biologics
Biotech firm developing antibody therapeutics.
- analystJefferies
Investment bank that reiterated a Buy rating and raised the price target.



